Scoop: Biogen will finally publish its PhIII results for Aduhelm

Biogen quietly announced at a conference in Spain today that a manuscript of the Phase III results for the company’s controversial Alzheimer’s drug Aduhelm will finally be published, almost a year after the drug won its accelerated approval.